Title |
Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine
|
---|---|
Published in |
PLOS ONE, December 2012
|
DOI | 10.1371/journal.pone.0050221 |
Pubmed ID | |
Authors |
Benita Wolf, Adrian Schwarzer, Anik L. Côté, Thomas H. Hampton, Thomas Schwaab, Eduardo Huarte, Craig R. Tomlinson, Jiang Gui, Jan L. Fisher, Camilo E. Fadul, Joshua W. Hamilton, Marc S. Ernstoff |
Abstract |
Lymphocytes are a key component of the immune system and their differentiation and function are directly influenced by cancer. We examined peripheral blood lymphocyte (PBL) gene expression as a biomarker of illness and treatment effect using the Affymetrix Human Gene ST1 platform in patients with metastatic renal cell carcinoma (mRCC) who received combined treatment with IL-2, interferon-?-2a and dendritic cell vaccine. We examined gene expression, cytokine levels in patient serum and lymphocyte subsets as determined by flow cytometry (FCM). Pre-treatment PBLs from patients with mRCC exhibit a gene expression profile and serum cytokine profile consistent with inflammation and proliferation not found in healthy donors (HD). PBL gene expression from patients with mRCC showed increased mRNA of genes involved with T-cell and T(REG)-cell activation pathways, which was also reflected in lymphocyte subset distribution. Overall, PBL gene expression post-treatment (POST) was not significantly different than pre-treatment (PRE). Nevertheless, treatment related changes in gene expression (post-treatment minus pre-treatment) revealed an increased expression of T-cell and B-cell receptor signaling pathways in responding (R) patients compared to non-responding (NR) patients. In addition, we observed down-regulation of T(REG)-cell pathways post-treatment in R vs. NR patients. While exploratory in nature, this study supports the hypothesis that enhanced inflammatory cytotoxic pathways coupled with blunting of the regulatory pathways is necessary for effective anti-cancer activity associated with immune therapy. This type of analysis can potentially identify additional immune therapeutic targets in patients with mRCC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 32 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 22% |
Researcher | 6 | 19% |
Student > Doctoral Student | 3 | 9% |
Other | 3 | 9% |
Student > Postgraduate | 2 | 6% |
Other | 4 | 13% |
Unknown | 7 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 28% |
Agricultural and Biological Sciences | 6 | 19% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Immunology and Microbiology | 2 | 6% |
Computer Science | 1 | 3% |
Other | 2 | 6% |
Unknown | 9 | 28% |